Quentin Kimmerlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Quentin Kimmerlin has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- François Lanza
Institut National de la Santé et de la Recherche Médicale, Etablissement Français du Sang Grand Est, Unité Mixte de Recherche-S 1255, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
4 shared publications - Radek C. Skoda
Baylor College of Medicine Dan L Duncan Comprehensive Cancer Center Houston Texas USA
4 shared publications Sylvie Moog
Université de Strasbourg, Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang (EFS) Grand-Est, Biologie et Pharmacologie des Plaquettes Sanguines (BPPS), Unité Mixte de Recherche (UMR)-S1255, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
4 shared publicationsTiago Almeida Fonseca
Department of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland
4 shared publications- Alexandre Guy
Department of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland
3 shared publications Hui Hao-Shen
Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland
3 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Wiley in HemaSphere
- Vol. 10 (5)
A single JAK2 ‐V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non‐conditioned recipient mice
Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells (HSCs) that are most frequently caused by acquired somatic mutations in JAK2 . A number of conditional mouse models of JAK2 ‐V617F‐driven MPN have been generated that rely on Cre‐LoxP‐mediated activation, resulting in polyclonal disease. To more closely mimic the monoclonal origin of human MPN, transplantations of single purified JAK2 ‐mutant HSCs or bone marrow (BM) at limiting dilutions into lethally irradiated recipient mice have been previously performed. However, irradiation is known to alter the BM microenvironment and also to induce transient aplasia accompanied by elevated cytokine levels that promote the expansion of the mutant clone. To overcome these limitations, we examined whether JAK2‐ V617F‐mutant HSCs are able to engraft and initiate MPN in non‐conditioned recipients. We found that BM from two different MPN models, one expressing the human JAK2 ‐V617F, and another expressing the mouse Jak2 ‐V617F, efficiently engrafted and initiated MPN in non‐irradiated immunocompromised Rag2 −/− recipients. MPN evolved even in transplantations at limiting dilutions, showing the high competitiveness of single JAK2 ‐mutant HSCs. In contrast, BM from mice expressing the human JAK2 ‐V617F failed to engraft in non‐conditioned immunocompetent C57BL/6 mice, while BM from mice expressing the mouse Jak2 ‐V617F engrafted and initiated MPN, suggesting that mouse JAK2‐V617F protein, which differs from the endogenous JAK2 in only one amino acid, was tolerated. Our results show that JAK2 ‐V617F mutant HSCs can outcompete resident non‐mutated HSCs even in the absence of elevated cytokine levels and without the need of emptying stem cell niches by irradiation.
- 28 April 2026
- Published by Wiley in HemaSphere
- Vol. 10 (5)
Open AccessA single JAK2 ‐V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non‐conditioned recipient mice
Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells (HSCs) that are most frequently caused by acquired somatic mutations in JAK2 . A number of conditional mouse models of JAK2 ‐V617F‐driven MPN have been generated that rely on Cre‐LoxP‐mediated activation, resulting in polyclonal disease. To more closely mimic the monoclonal origin of human MPN, transplantations of single purified JAK2 ‐mutant HSCs or bone marrow (BM) at limiting dilutions into lethally irradiated recipient mice have been previously performed. However, irradiation is known to alter the BM microenvironment and also to induce transient aplasia accompanied by elevated cytokine levels that promote the expansion of the mutant clone. To overcome these limitations, we examined whether JAK2‐ V617F‐mutant HSCs are able to engraft and initiate MPN in non‐conditioned recipients. We found that BM from two different MPN models, one expressing the human JAK2 ‐V617F, and another expressing the mouse Jak2 ‐V617F, efficiently engrafted and initiated MPN in non‐irradiated immunocompromised Rag2 −/− recipients. MPN evolved even in transplantations at limiting dilutions, showing the high competitiveness of single JAK2 ‐mutant HSCs. In contrast, BM from mice expressing the human JAK2 ‐V617F failed to engraft in non‐conditioned immunocompetent C57BL/6 mice, while BM from mice expressing the mouse Jak2 ‐V617F engrafted and initiated MPN, suggesting that mouse JAK2‐V617F protein, which differs from the endogenous JAK2 in only one amino acid, was tolerated. Our results show that JAK2 ‐V617F mutant HSCs can outcompete resident non‐mutated HSCs even in the absence of elevated cytokine levels and without the need of emptying stem cell niches by irradiation.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation biochimique et fonctionnelle du code tubuline des plaquettes sanguines
Les plaquettes sanguines sont de petits fragments cellulaires anucléés qui assurent l’hémostase. Elles sont produites par les mégacaryocytes de la moelle osseuse à l’issue d’un processus complexe qui comprend de profonds remaniements du cytosquelette de microtubule. L’un des derniers évènements consiste en la formation d’une structure circulaire et sous-membranaire unique aux mammifères, appelée bande marginale, dont le rôle est d’assurer la forme discoïde typique des plaquettes circulantes. D’un point de vue mécanistique, l’ensemble des remaniements microtubulaires seraient contrôlés par un code tubuline propre au lignage plaquettaire. Dans ce travail, nous montrons que i) les isotypes de tubuline α4A et β1 coopèrent ensemble pour assurer l’assemblage de la bande marginale, et que leur double inactivation chez la souris entraine la formation de plaquettes sphériques dépourvues de bande marginale et incapables d’assurer l’hémostase ; ii) des mutations dans l’isotype α8 perturbent la biogenèse des plaquettes et leur bande marginale, causant des macrothrombopénies chez l’Homme et ; iii) plusieurs modifications post-traductionnelles de tubuline sont retrouvées dans la lignée plaquettaire, dont les rôles restent encore à élucider. Ensemble, nos résultats pourraient avoir des applications directes dans les pathologies plaquettaires et la transfusion.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Caractérisation biochimique et fonctionnelle du code tubuline des plaquettes sanguines
Les plaquettes sanguines sont de petits fragments cellulaires anucléés qui assurent l’hémostase. Elles sont produites par les mégacaryocytes de la moelle osseuse à l’issue d’un processus complexe qui comprend de profonds remaniements du cytosquelette de microtubule. L’un des derniers évènements consiste en la formation d’une structure circulaire et sous-membranaire unique aux mammifères, appelée bande marginale, dont le rôle est d’assurer la forme discoïde typique des plaquettes circulantes. D’un point de vue mécanistique, l’ensemble des remaniements microtubulaires seraient contrôlés par un code tubuline propre au lignage plaquettaire. Dans ce travail, nous montrons que i) les isotypes de tubuline α4A et β1 coopèrent ensemble pour assurer l’assemblage de la bande marginale, et que leur double inactivation chez la souris entraine la formation de plaquettes sphériques dépourvues de bande marginale et incapables d’assurer l’hémostase ; ii) des mutations dans l’isotype α8 perturbent la biogenèse des plaquettes et leur bande marginale, causant des macrothrombopénies chez l’Homme et ; iii) plusieurs modifications post-traductionnelles de tubuline sont retrouvées dans la lignée plaquettaire, dont les rôles restent encore à élucider. Ensemble, nos résultats pourraient avoir des applications directes dans les pathologies plaquettaires et la transfusion.
- Open Access
Single JAK2 -V617F hematopoietic stem cells can initiate MPN in transplantations into non-conditioned recipient mice
Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells (HSC) that are most frequently caused by acquired somatic mutations in JAK2 . A number of conditional mouse models of JAK2- V617F-driven MPN have been generated that rely on Cre-LoxP mediated activation, resulting in polyclonal disease. To more closely mimic the monoclonal origin of human MPN, transplantations of single purified JAK2 -mutant HSCs or bone marrow (BM) at limiting dilutions into lethally irradiated recipient mice have been previously performed. However, irradiation is known to alter the BM microenvironment and also to induce transient aplasia accompanied by elevated cytokine levels that promotes the expansion of the mutant clone. To overcome these limitations, we examined whether JAK2- V617F-mutant HSCs are able to engraft and initiate MPN in non-conditioned recipients. We found that BM from two different MPN models, one expressing the human JAK2 -V617F, and another expressing the mouse Jak2 -V617F, efficiently engrafted and initiated MPN in non-irradiated immunocompromised Rag2 −/− recipients. MPN evolved even in transplantations at limiting dilutions, showing high competitiveness of single JAK2 -mutant HSCs. Thus, JAK2 -V617F mutant HSCs can outcompete resident non-mutated HSCs in the absence of elevated cytokine levels and without the need of emptying stem cell niches by irradiation. However, only BM from mice expressing the mouse Jak2 -V617F engrafted and initiated disease in non-conditioned C57BL/6 mice, while BM from mice expressing the human JAK2 -V617F was rejected, indicating that mouse Jak2 -V617F is ignored by the immune surveillance. These results provide a possible explanation why JAK2 -V617F is so frequently found in healthy individuals with clonal hematopoiesis.
Open AccessSingle JAK2 -V617F hematopoietic stem cells can initiate MPN in transplantations into non-conditioned recipient mice
Myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells (HSC) that are most frequently caused by acquired somatic mutations in JAK2 . A number of conditional mouse models of JAK2- V617F-driven MPN have been generated that rely on Cre-LoxP mediated activation, resulting in polyclonal disease. To more closely mimic the monoclonal origin of human MPN, transplantations of single purified JAK2 -mutant HSCs or bone marrow (BM) at limiting dilutions into lethally irradiated recipient mice have been previously performed. However, irradiation is known to alter the BM microenvironment and also to induce transient aplasia accompanied by elevated cytokine levels that promotes the expansion of the mutant clone. To overcome these limitations, we examined whether JAK2- V617F-mutant HSCs are able to engraft and initiate MPN in non-conditioned recipients. We found that BM from two different MPN models, one expressing the human JAK2 -V617F, and another expressing the mouse Jak2 -V617F, efficiently engrafted and initiated MPN in non-irradiated immunocompromised Rag2 −/− recipients. MPN evolved even in transplantations at limiting dilutions, showing high competitiveness of single JAK2 -mutant HSCs. Thus, JAK2 -V617F mutant HSCs can outcompete resident non-mutated HSCs in the absence of elevated cytokine levels and without the need of emptying stem cell niches by irradiation. However, only BM from mice expressing the mouse Jak2 -V617F engrafted and initiated disease in non-conditioned C57BL/6 mice, while BM from mice expressing the human JAK2 -V617F was rejected, indicating that mouse Jak2 -V617F is ignored by the immune surveillance. These results provide a possible explanation why JAK2 -V617F is so frequently found in healthy individuals with clonal hematopoiesis.
- Open Access
- 14 March 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (6) , 2025-2034
Importance of tubulin detyrosination in platelet biogenesis
- 14 March 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (6) , 2025-2034
Open AccessImportance of tubulin detyrosination in platelet biogenesis
- 11 March 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (4) , 876-887
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F
Therapy with pegylated interferon alpha (pegIFNα) can induce a deep molecular response in a subset of patients with myeloproliferative neoplasms (MPN). Here we investigated the role of Socs2, a negative regulator of cytokine signaling, in modulating the response to pegIFNα in a JAK2-V617F mouse model of MPN. Deleting Socs2 in JAK2-V617F mice resulted in increased sensitivity to cytokines, without causing significant alterations in the MPN phenotype. When subjected to pegIFNα, the loss of Socs2 enhanced the depletion of JAK2-mutant hematopoietic stem cells (HSCs), evidenced by reduced chimerism in peripheral blood and bone marrow compared to vehicle controls. Additionally, pegIFNα-treated Socs2-deficient JAK2-mutant HSCs exhibited functional impairments in secondary transplantations, reflecting long-term detrimental decline of their stemness. These findings demonstrate that loss of Socs2 enhances the effectiveness of pegIFNα in depleting the JAK2-mutant HSC clone. In line with the genetic ablation of Socs2, the SOCS2 inhibitor MN714 combined with IFNα exhibited better efficacy than IFNα alone in reducing the output of CD34+ cells from PV patients in vitro. Targeting SOCS2 could therefore improve therapeutic responsiveness in MPN patients receiving interferon therapy.
- 11 March 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (4) , 876-887
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F
Therapy with pegylated interferon alpha (pegIFNα) can induce a deep molecular response in a subset of patients with myeloproliferative neoplasms (MPN). Here we investigated the role of Socs2, a negative regulator of cytokine signaling, in modulating the response to pegIFNα in a JAK2-V617F mouse model of MPN. Deleting Socs2 in JAK2-V617F mice resulted in increased sensitivity to cytokines, without causing significant alterations in the MPN phenotype. When subjected to pegIFNα, the loss of Socs2 enhanced the depletion of JAK2-mutant hematopoietic stem cells (HSCs), evidenced by reduced chimerism in peripheral blood and bone marrow compared to vehicle controls. Additionally, pegIFNα-treated Socs2-deficient JAK2-mutant HSCs exhibited functional impairments in secondary transplantations, reflecting long-term detrimental decline of their stemness. These findings demonstrate that loss of Socs2 enhances the effectiveness of pegIFNα in depleting the JAK2-mutant HSC clone. In line with the genetic ablation of Socs2, the SOCS2 inhibitor MN714 combined with IFNα exhibited better efficacy than IFNα alone in reducing the output of CD34+ cells from PV patients in vitro. Targeting SOCS2 could therefore improve therapeutic responsiveness in MPN patients receiving interferon therapy.
- Open Access
- 14 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (9) , 2312-2325
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
Hyperproliferation of myeloid and erythroid cells in myeloproliferative neoplasms (MPN) driven by the JAK2-V617F mutation is associated with altered metabolism. Given the central role of glutamine in anabolic and catabolic pathways, we examined the effects of pharmacologically inhibiting glutaminolysis, that is, the conversion of glutamine (Gln) to glutamate (Glu), using CB-839, a small molecular inhibitor of the enzyme glutaminase (GLS). We show that CB-839 strongly reduced the mitochondrial respiration rate of bone marrow cells from JAK2-V617F mutant (VF) mice, demonstrating a marked dependence of these cells on Gln-derived ATP production. Consistently, in vivo treatment with CB-839 normalized blood glucose levels, reduced splenomegaly and decreased erythrocytosis in VF mice. These effects were more pronounced when CB-839 was combined with the JAK1/2 inhibitor ruxolitinib or the glycolysis inhibitor 3PO, indicating possible synergies when cotargeting different metabolic and oncogenic pathways. Furthermore, we show that the inhibition of glutaminolysis with CB-839 preferentially lowered the proportion of JAK2-mutant hematopoietic stem cells (HSCs). The total number of HSCs was decreased by CB-839, primarily by reducing HSCs in the G1 phase of the cell cycle. CB-839 in combination with ruxolitinib also strongly reduced myelofibrosis at later stages of MPN. In line with the effects shown in mice, proliferation of CD34+ hematopoietic stem and progenitor cells from polycythemia vera patients was inhibited by CB-839 at nanomolar concentrations. These data suggest that inhibiting GLS alone or in combination with inhibitors of glycolysis or JAK2 inhibitors represents an attractive new therapeutic approach to MPN.
- 14 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (9) , 2312-2325
Open AccessThe glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
Hyperproliferation of myeloid and erythroid cells in myeloproliferative neoplasms (MPN) driven by the JAK2-V617F mutation is associated with altered metabolism. Given the central role of glutamine in anabolic and catabolic pathways, we examined the effects of pharmacologically inhibiting glutaminolysis, that is, the conversion of glutamine (Gln) to glutamate (Glu), using CB-839, a small molecular inhibitor of the enzyme glutaminase (GLS). We show that CB-839 strongly reduced the mitochondrial respiration rate of bone marrow cells from JAK2-V617F mutant (VF) mice, demonstrating a marked dependence of these cells on Gln-derived ATP production. Consistently, in vivo treatment with CB-839 normalized blood glucose levels, reduced splenomegaly and decreased erythrocytosis in VF mice. These effects were more pronounced when CB-839 was combined with the JAK1/2 inhibitor ruxolitinib or the glycolysis inhibitor 3PO, indicating possible synergies when cotargeting different metabolic and oncogenic pathways. Furthermore, we show that the inhibition of glutaminolysis with CB-839 preferentially lowered the proportion of JAK2-mutant hematopoietic stem cells (HSCs). The total number of HSCs was decreased by CB-839, primarily by reducing HSCs in the G1 phase of the cell cycle. CB-839 in combination with ruxolitinib also strongly reduced myelofibrosis at later stages of MPN. In line with the effects shown in mice, proliferation of CD34+ hematopoietic stem and progenitor cells from polycythemia vera patients was inhibited by CB-839 at nanomolar concentrations. These data suggest that inhibiting GLS alone or in combination with inhibitors of glycolysis or JAK2 inhibitors represents an attractive new therapeutic approach to MPN.
- 24 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (21) , 2290-2299
Loss of α4A- and β1-tubulins leads to severe platelet spherocytosis and strongly impairs hemostasis in mice
Native circulating blood platelets present with a discoid flat morphology maintained by a submembranous peripheral ring of microtubules, named marginal band. The functional importance of this particular shape is still debated, but it was initially hypothesized to facilitate platelet interaction with the injured vessel wall and to contribute to hemostasis. The importance of the platelet discoid morphology has since been questioned on the absence of clear bleeding tendency in mice lacking the platelet-specific β1-tubulin isotype, which exhibits platelets with a thinner marginal band and an ovoid shape. Here, we generated a mouse model inactivated for β1-tubulin and α4A-tubulin, an α-tubulin isotype strongly enriched in platelets. These mice present with fully spherical platelets completely devoid of a marginal band. In contrast to the single knockouts, the double deletion resulted in a severe bleeding defect in a tail-clipping assay, which was not corrected by increasing the platelet count to normal values by the thrombopoietin-analog romiplostim. In vivo, thrombus formation was almost abolished in a ferric chloride–injury model, with only a thin layer of loosely packed platelets, and mice were protected against death in a model of thromboembolism. In vitro, platelets adhered less efficiently and formed smaller-sized and loosely assembled aggregates when perfused over von Willebrand factor and collagen matrices. In conclusion, this study shows that blood platelets require 2 unique α- and β-tubulin isotypes to acquire their characteristic discoid morphology. Lack of these 2 isotypes has a deleterious effect on flow-dependent aggregate formation and stability, leading to a severe bleeding disorder.
- 24 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (21) , 2290-2299
Loss of α4A- and β1-tubulins leads to severe platelet spherocytosis and strongly impairs hemostasis in mice
Native circulating blood platelets present with a discoid flat morphology maintained by a submembranous peripheral ring of microtubules, named marginal band. The functional importance of this particular shape is still debated, but it was initially hypothesized to facilitate platelet interaction with the injured vessel wall and to contribute to hemostasis. The importance of the platelet discoid morphology has since been questioned on the absence of clear bleeding tendency in mice lacking the platelet-specific β1-tubulin isotype, which exhibits platelets with a thinner marginal band and an ovoid shape. Here, we generated a mouse model inactivated for β1-tubulin and α4A-tubulin, an α-tubulin isotype strongly enriched in platelets. These mice present with fully spherical platelets completely devoid of a marginal band. In contrast to the single knockouts, the double deletion resulted in a severe bleeding defect in a tail-clipping assay, which was not corrected by increasing the platelet count to normal values by the thrombopoietin-analog romiplostim. In vivo, thrombus formation was almost abolished in a ferric chloride–injury model, with only a thin layer of loosely packed platelets, and mice were protected against death in a model of thromboembolism. In vitro, platelets adhered less efficiently and formed smaller-sized and loosely assembled aggregates when perfused over von Willebrand factor and collagen matrices. In conclusion, this study shows that blood platelets require 2 unique α- and β-tubulin isotypes to acquire their characteristic discoid morphology. Lack of these 2 isotypes has a deleterious effect on flow-dependent aggregate formation and stability, leading to a severe bleeding disorder.
- 7 January 2022
- Published by Taylor & Francis in Platelets
- Vol. 33 (6) , 833-840
Glycoprotein V : the unsolved GPV puzzle
Glycoprotein V (GPV) is a highly expressed 82 KDa platelet surface transmembrane protein which is loosely attached to the GPIb-IX complex. Despite remaining questions concerning its function, GPV presents several unique features which have repercussions in hematology, atherothrombosis, immunology and transfusion. GPV is specifically expressed in platelets and megakaryocytes and is an ideal marker and reporter gene for the late stages of megakaryopoiesis. The ectodomain of GPV can be released by a number of proteases, namely thrombin, elastase and ADAM10 and 17. Although it was originally proposed as a thrombin receptor, this hypothesis was abandoned since thrombin activation was preserved after blockade of GPV cleavage and in Gp5 knockout mice. The combined potential of GPV to reflect the direct action of thrombin, platelet exposure to strong agonists and inflammatory conditions has led one to evaluate its utility as a marker in the context of atherothrombosis. Increased plasma levels of soluble GPV have notably been recorded in myocardial infarction, stroke and venous thromboembolism. It is also highly valued in transfusion to monitor platelet storage lesions. GPV presents several polymorphisms, which are a possible source of alloantibodies, while autoantibodies have been frequently detected in immune thrombocytopenia. The real biological function of this glycoprotein nevertheless remains an enigma, despite the respectively decreased and increased responses to low concentrations of collagen and thrombin observed in Gp5 knockout mice. Current studies are exploring its role in modulating general or VWF-induced platelet signaling, which could bear relevance in thrombosis and platelet clearance.
- 7 January 2022
- Published by Taylor & Francis in Platelets
- Vol. 33 (6) , 833-840
Glycoprotein V : the unsolved GPV puzzle
Glycoprotein V (GPV) is a highly expressed 82 KDa platelet surface transmembrane protein which is loosely attached to the GPIb-IX complex. Despite remaining questions concerning its function, GPV presents several unique features which have repercussions in hematology, atherothrombosis, immunology and transfusion. GPV is specifically expressed in platelets and megakaryocytes and is an ideal marker and reporter gene for the late stages of megakaryopoiesis. The ectodomain of GPV can be released by a number of proteases, namely thrombin, elastase and ADAM10 and 17. Although it was originally proposed as a thrombin receptor, this hypothesis was abandoned since thrombin activation was preserved after blockade of GPV cleavage and in Gp5 knockout mice. The combined potential of GPV to reflect the direct action of thrombin, platelet exposure to strong agonists and inflammatory conditions has led one to evaluate its utility as a marker in the context of atherothrombosis. Increased plasma levels of soluble GPV have notably been recorded in myocardial infarction, stroke and venous thromboembolism. It is also highly valued in transfusion to monitor platelet storage lesions. GPV presents several polymorphisms, which are a possible source of alloantibodies, while autoantibodies have been frequently detected in immune thrombocytopenia. The real biological function of this glycoprotein nevertheless remains an enigma, despite the respectively decreased and increased responses to low concentrations of collagen and thrombin observed in Gp5 knockout mice. Current studies are exploring its role in modulating general or VWF-induced platelet signaling, which could bear relevance in thrombosis and platelet clearance.
- 26 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (2) , 461-469
Mutations in the most divergent α‐tubulin isotype, α8‐tubulin, cause defective platelet biogenesis
- 26 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (2) , 461-469
Mutations in the most divergent α‐tubulin isotype, α8‐tubulin, cause defective platelet biogenesis
- 20 May 2021
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 171
Isolation of Mouse Megakaryocyte Progenitors
This method describes the purification by flow cytometry of MEP and MKp from mice femurs, tibias, and pelvic bones.
- 20 May 2021
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 171
Isolation of Mouse Megakaryocyte Progenitors
This method describes the purification by flow cytometry of MEP and MKp from mice femurs, tibias, and pelvic bones.